Open Genome

The email hit Anne Wojcicki’s phone at 8:17 a.m. on a gray November morning in 2013. Fog clung to the hills and refused to lift. She stood in the open expanse of the Mountain View offices of 23andMe, the company she had co-founded to let ordinary people spit into a tube and receive their own genetic information without a doctor’s permission. Fluorescent lights already felt too bright. The subject line was clinical, almost polite in its finality.

Warning Letter

She read the first paragraph once. Then again. The Food and Drug Administration ordered her company to stop providing health-related genetic reports at once. The spit kits that had promised a direct window into personal biology were now, in the eyes of the federal government, unapproved medical devices. Everything Anne had built to put genetic information into the hands of individuals rather than institutions was under immediate threat of being shut down.

Anne walked the length of the floor without speaking. Employees glanced up and then away. Some already knew. The letter had circulated far enough that the news moved the way bad news always moved in Silicon Valley—fast, incomplete, edged with the particular dread of people who had staked careers on a vision that might now be illegal.

She stopped at the long table where the morning stand-up usually happened and set the phone down. The screen still glowed with the dense legal language.

Cease marketing the health reports.

Take corrective action.

Possible further enforcement.

A young product manager near the kitchen cleared his throat. “Do the people who already have their reports get to keep them?”

Anne did not turn. “We will follow the letter of the law.”

The words came out steadier than she felt. She could feel the weight of every saliva sample in the warehouse, every barcode, every customer who had already opened an email that began with the words “Your health reports.”

Outside the glass walls the parking lot was full. Inside the air felt thin. For a long moment she remained motionless at the table, the fluorescent glare pressing against her eyelids. The contrast between this morning and the one seven years earlier struck her with physical force. In 2006 the vision had been pure. Now the same key she had offered people had been declared contraband. The idealism that once felt unassailable looked, in the cold light of the warning letter, almost naïve—yet the naivety still burned.

Her phone buzzed again. A text from a reporter. Then another. The separation from Sergey Brin—her husband, the Google co-founder whose early support and scientific curiosity had once accelerated the company—was no longer private. The combination of personal fracture and corporate crisis was too perfect a story for anyone to ignore. Anne put the phone face-down. She had known the marriage was ending for months—longer, if she was honest—but the public timing felt like a second verdict. The woman who had preached ownership of one’s biology was now watching her private life become public property.

She closed her eyes. The office dissolved.

---

The year was 2006. The room was smaller, rented, fluorescent in a cheaper way. Across the scarred table sat Linda Avey, a biologist and entrepreneur who had already spent years inside the early genetics industry. Anne had first met her at a small biotech conference in San Francisco the year before, after a panel on the coming wave of consumer genetics. Linda had been one of the few people in the room who did not treat the idea of ordinary people accessing their own DNA as either a gimmick or a regulatory impossibility. They had talked for nearly two hours afterward. Linda understood the science and the minefields; Anne understood the institutional barriers that kept the science locked away. The conversation had continued in emails and late phone calls until the decision to build something together felt inevitable.

Against the wall leaned Paul Cusenza, an engineer whose skepticism was visible in the set of his shoulders. Linda had introduced him three months earlier, describing him as the person who would keep their ambition from outrunning the infrastructure required to support it. Paul had listened to Anne’s pitch once, asked a series of precise questions about data volume and security, and then agreed to join on the condition that no one pretended the technical problems would solve themselves.

Anne was talking faster than she usually allowed herself.

“People spit into a tube. They mail it. We sequence enough to give them ancestry, carrier status, risk markers. They own the data. Not the doctor. Not the hospital. Not the insurance company. Them.”

Linda looked up from the notebook she was already filling. “Regulators are going to care about the difference between information and diagnosis the second we start talking about disease risk.”

“Then we stay on the information side of the line,” Anne said. “But the line moves if we let them draw it alone.”

Paul pushed off the wall. “Storage. Security. Volume if this thing scales. You’re talking about people’s entire biological identity sitting on servers we control.”

“Exactly. That’s the point. Right now that identity sits in institutional black boxes. Hospitals decide what patients get to know. Pharma decides which diseases are profitable enough to study. Governments decide which research is fundable. The person living inside the body is the last one allowed to look.”

Linda tapped her pen. “You’re asking ordinary people to trust a startup with something most of them have never even seen.”

“I’m asking them to stop waiting for permission to see it.”

Paul exhaled. “And when the first customer gets a result they don’t know how to handle? When a physician who’s never ordered the test gets handed a printout and has no idea what to do with it?”

Anne met his eyes. “Then we’ll learn. But we don’t learn by asking the old system for permission first. The old system is designed to keep ordinary people dependent.”

Silence held for three full seconds.

Linda closed the notebook. “All right. We map the regulatory path carefully. No shortcuts.”

Paul nodded once. “I’ll start looking at infrastructure that won’t collapse if this actually works.”

Anne felt the decision settle in her chest. She would push the health reports. She would keep pushing even when the warnings came. The alternative—waiting for institutions to decide ordinary people were ready—was the thing she had left Wall Street to escape.

She had come to that conviction the hard way.

After Yale she had gone to Wall Street, not because she loved finance but because she wanted to understand the machinery that allocated capital to healthcare. She sat through endless meetings in which analysts discussed hospital systems and diagnostic companies as pure investment vehicles. Market share. Reimbursement rates. Pipeline risk. The patients were numbers. The diseases were categories.

One afternoon in a glass conference room overlooking the Hudson, the pattern became impossible to ignore. The managing director at the head of the table flipped through a thick binder of hospital-system comps.

“Reimbursement environment is tightening,” he said. “But the diagnostic side still has room if they control the referral channels. Anyone who lets patients order their own tests is leaving money on the table.”

A younger analyst nodded. “Direct access kills the intermediate margin. The whole model depends on the physician as gatekeeper.”

Another voice added, “And once you open the data to the patient, you lose pricing power on the interpretation. Better to keep the black box closed.”

Anne sat near the window, notebook open, pen still. She had heard versions of this conversation for months. Hospital systems were valued on their ability to capture patients and keep information flowing through controlled channels. Diagnostic companies were valued on their ability to own the test and the result. Nowhere in the discussion did anyone ask what the person whose blood or tissue was being analyzed might want to know, or whether they had any right to see the data without institutional permission.

She looked down at her own notes—family medical history she had started jotting in the margins during earlier meetings. Gaps everywhere. Questions no one in the system seemed equipped or motivated to answer for an ordinary person. A single genetic variant could rewrite a life, yet the institutions that held the relevant information treated it as proprietary inventory.

The managing director closed the binder. “Bottom line: any model that gives the patient direct control is a margin destroyer. We stay on the institutional side.”

Anne closed her notebook. Outside the window the river moved slowly under a gray sky. She realized, with a clarity that felt almost physical, that she could not stay. The system she was analyzing was designed to keep ordinary people dependent. If she remained inside it, she would spend her career optimizing the dependence. The alternative was to build something that started from the opposite premise: that the person living inside the body should be the first, not the last, to look at the code written there.

She resigned within the year.

---

Linda brought the scientific rigor and the early connections. Paul brought the engineering temperament that kept the vision from floating free of practical constraints. Anne brought the relentless insistence that the consumer—not the system—was the point. They incorporated. They raised the first money. They designed the kit.

The name came almost as an afterthought one afternoon while they were still arguing over positioning. Twenty-three chromosomes. The full set that made a person who they were. “23andMe,” Anne said, testing it aloud. Not a laboratory name. Not a clinical name. A name that put the individual at the center. Linda had nodded. Paul had shrugged and written it down. It stuck.

The months that followed were harder than the decision itself.

Investors listened politely and then passed. One partner at a well-known firm told them, after a short meeting, that the idea was “interesting science, terrible business.” Another asked whether they had considered partnering with a hospital system instead of trying to go around it. Friends in the Valley called the concept impossible—too regulated, too personal, too far outside the comfort zone of both medicine and consumer tech. A former colleague from Wall Street emailed Anne a single line: "You’re going to get crushed between the FDA and the doctors."

Building the first kit proved messier still. The early prototypes leaked. The instructions confused the first test users. The lab partner missed deadlines. Cash-flow projections that had looked manageable on a whiteboard became tight the moment real invoices arrived. There were weeks when Anne, Linda, and Paul sat in the rented space late at night recalculating how long they could keep the lights on if the next small raise slipped. Paul once looked up from a server-cost spreadsheet and said, without heat, “If this doesn’t work, we will have spent a year building the world’s most expensive way to tell people they have European ancestry.”

Anne did not argue. She simply kept the next task in front of them. Redesign the tube seal. Simplify the return packaging. Tighten the consent language until it was clear enough for someone who had never thought about genetic data before. They worked through the rejections and the technical failures the same way they had worked through the original skepticism: by treating every obstacle as temporary and the premise as non-negotiable.

Then the first kits shipped.

A small batch. Real customers. Real saliva samples moving through the system they had built. The night the first clean reports came back, the three of them stood in the rented office looking at the data on a shared screen. No one spoke for a long moment. The idea that had been dismissed as impossible was no longer theoretical. Ordinary people had mailed in their biology and were about to receive information that institutions had long treated as their exclusive domain. The excitement was quiet, almost stunned. It felt less like victory than like the first proof that the refusal to wait for permission might actually hold.

Somewhere in the middle of that scramble, Sergey Brin entered the frame more fully than he had before. They had known each other socially—Silicon Valley was smaller then—but the launch of the company tightened the connection. One evening, after the first prototype reports had come back clean, he stood in the same rented space looking at the early data on a laptop screen.

“You know what this could become,” he said.

Anne looked up. “I know what it already is.”

“No. You don’t.”

“Then tell me.”

“A database this size, if it grows, could change medicine. Real research scale.”

“Only if people trust us enough to give us their data in the first place.”

Sergey smiled, the particular smile of someone who already saw three moves ahead. “That’s not the only thing that matters.”

“It’s the first thing that matters,” Anne said. “Everything else is downstream.”

The early customers received results that felt like small earthquakes. A woman in Ohio learned her ancestry was not the story her family had told for three generations. A man in California discovered a carrier status that explained a string of miscarriages. Another customer found a distant relative and, within months, an entire branch of family she had never known. Some of the revelations were joyful. Some were destabilizing. A few sent people running to physicians who had never ordered the test and did not know what to do with the results. Anne collected the stories the way other founders collected metrics. Each one proved the thesis: knowledge changed the relationship between a person and their own body.

She pushed harder. Ancestry was popular, but health was the real disruption. In a late strategy meeting she laid out the expanded marker list.

Linda’s voice was careful. “Every additional health claim raises the regulatory temperature. We are already being watched.”

Paul added, “The infrastructure is holding, but barely. If volume spikes and we haven’t locked down security and interpretation layers, we create the exact problem the agencies are waiting for.”

Anne listened, nodded, and kept the expansion on the table. “Slowing down is a form of surrender. Every month we delay is another month the old system keeps its monopoly on biological knowledge.”

The relationship with Sergey deepened in parallel. They married. They had children. The private and the professional braided together until it was difficult to tell where one ended and the other began. Google’s investment accelerated the trajectory. Yet the blending created new pressures. Anne’s absolute certainty about the mission sometimes collided with the practical realities of institutional investors and public visibility. The marriage absorbed some of that tension and reflected it back.

Her sister Susan Wojcicki, already rising inside Google, added another current. Family gatherings carried undercurrents of pride and unspoken comparison. Their mother, Esther Wojcicki, remained a steady presence—practical, resilient, a reminder of earlier chapters in which the Wojcicki women had navigated systems not designed for them.

By 2010 and 2011 the database was growing at a pace that felt historic. Anne saw the path clearly: consumer empowerment first, scientific discovery as the natural consequence. She underestimated how fiercely the institutions would defend their territory. Warning letters arrived. Meetings with the FDA grew more pointed. Questions about analytical validity, clinical validity, the difference between information and diagnosis. Anne treated them as obstacles to be navigated rather than signals to slow down. The reports continued to expand. The marketing continued to emphasize empowerment.

---

In the present, standing in the Mountain View office with the FDA letter still open on her phone, Anne could trace every decision that had led here. The aggressive expansion of health reports. The refusal to accept physician gatekeeping as permanent. The belief that the public’s right to know outweighed the regulators’ preference for controlled release of information. She had not set out to provoke a crisis. She had set out to make the crisis of institutional control visible by offering an alternative. Now the alternative itself was under threat of erasure.

The letter on the screen was not an isolated regulatory action. It was the direct consequence of the philosophy she had carried from Wall Street boardrooms into a rented office in 2006, through the first customer results, through the clashes with Linda’s caution and Paul’s engineering concerns, through the marriage that had fused personal and professional ambition, through every decision to expand rather than retreat. The institutions she had set out to disintermediate had simply exercised the power they still held. The collision was no longer theoretical. It was here, in the fluorescent light of the office, in the public exposure of her separation, in the sudden uncertainty on every employee’s face.

Anne picked up the phone again, turned it face-up, and looked at the dense paragraphs of the warning once more. She did not yet know the precise shape of the fight ahead. She knew only that the fight itself was the inevitable result of the choice she had made years earlier: that people deserved direct ownership of their own biology, and that institutions would never surrender that ownership without a contest.

The contest had arrived.

She stood in the middle of it, the fog still pressing against the windows, and understood that everything from this moment forward would be measured by whether she continued to refuse.